Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clozapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | DRD4 | P21917 | 7/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clozapine SCHEMBL8397 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL20876213 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29360001 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29590817 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29433929 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28700741 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28648626 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29180214 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL140458 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29041024 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3691651-A1 | STABLE SOLUTIONS OF MULTICYCLIC ANTIDEPRESSANTS | Leyden Technologies B.V. (NL) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019068859-A1 | STABLE SOLUTIONS OF MULTICYCLIC ANTIDEPRESSANTS | LEYDEN TECHNOLOGIES B.V. (NL) | 2019-04-11 | — | — | WO | disclosed |
| CN-109316482-A | Clozapine is in preparation tumor therapeutic agent and its as the application in autophagy inhibitor, pharmaceutical composition | 徐州医科大学 | 2019-02-12 | — | — | CN | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-101398414-B | Method for qualitatively screening 242 kinds of compounds by liquid phase chromatography-mass spectra at the same times | CRIMINAL INVEST DEPT OF SHANGHAI POLICE STATION | 2011-07-20 | — | — | CN | disclosed |
| CN-101398414-A | Method for qualitatively screening 242 kinds of compounds by liquid phase chromatography-mass spectra at the same times | CRIMINAL INVEST GENERAL UNIT O (CN) | 2009-04-01 | — | — | CN | disclosed |
| EP-1817427-A2 | METHOD FOR DETERMINING GENOTOXICITY | F. Hoffmann-Roche AG (CH) | 2007-08-15 | — | — | EP | disclosed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006056340-A2 | METHOD FOR DETERMINING GENOTOXICITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1014977-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LIMITED (GB) | 2000-07-05 | — | — | EP | disclosed |
| EP-1014977-A4 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000022109-A1 | MOLECULAR MARKERS FOR DETERMINING A PATIENT'S RISK OF DEVELOPING AGRANULOCYTOSIS | MILLENNIUM PREDICTIVE MEDICINE, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
| US-5861423-A | SIDE EFFECT REDUCTION; ADMINISTERING TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; ATTENTION DEFICIT DISORDER, SCHIZOPHRENIA | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1999-01-19 | — | — | US | disclosed |
| WO-1998007426-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP, LTD. (GB) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | SLC6A4, SLC1A2, SLC6A2 | DRD2 172/4885HTR2A 6/4885CHRM1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.